Bionano Genomics (BNGO) Cost of Revenue (2017 - 2026)

Bionano Genomics has disclosed Cost of Revenue across 10 years of filings, most recently posting $3.4 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $3.4 million, down 2.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.2 million (down 34.82% YoY), and the FY2025 annual result was $15.3 million, down 49.59% from the prior year.
• Cost of Revenue came in at $3.4 million for Q1 2026 at Bionano Genomics, down from $4.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $14.5 million in Q3 2024 to a low of $157000.0 in Q4 2024.
• The 5-year median for Cost of Revenue is $5.2 million (2022), against an average of $5.5 million.
• Across the five-year window, Cost of Revenue sank 98.1% in 2024 and soared 2799.36% in 2025, its largest moves.
• Bionano Genomics' Cost of Revenue stood at $6.4 million in 2022, then climbed by 29.22% to $8.3 million in 2023, then tumbled by 98.1% to $157000.0 in 2024, then jumped by 2799.36% to $4.6 million in 2025, then decreased by 24.54% to $3.4 million in 2026.
• The last three Cost of Revenue figures came in at $3.4 million (Q1 2026), $4.6 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.